Literature DB >> 2504465

Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis.

C de la Piedra1, R Torres, A Rapado, M Diaz Curiel, N Castro.   

Abstract

Serum tartrate-resistant acid phosphatase (sTr-AcP) and bone mineral content (BMC) were measured in 29 women with postmenopausal osteoporosis and in 12 control women. Serum Tr-AcP was higher in osteoporotic patients than in controls and a negative linear correlation was found between sTr-AcP and BMC in osteoporotic women. These results suggest that sTr-AcP could be a useful marker for bone loss and consequently, for the measure of bone resorption rate in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504465     DOI: 10.1007/bf02556662

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum: biological variations and reference limits.

Authors:  F Schiele; Y Artur; A Y Floc'h; G Siest
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

2.  Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis.

Authors:  J J Stĕpán; J Lachmanová; M Straková; V Pacovský
Journal:  Bone Miner       Date:  1987-11

3.  Acid phosphatases in human plasma.

Authors:  C Y Li; R A Chuda; W K Lam; L T Yam
Journal:  J Lab Clin Med       Date:  1973-09

4.  Tartrate-resistant acid phosphatase activity in rat osteoblasts and osteocytes.

Authors:  P Bianco; P Ballanti; E Bonucci
Journal:  Calcif Tissue Int       Date:  1988-09       Impact factor: 4.333

5.  Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism.

Authors:  J J Stĕpan; E Silinková-Málková; T Havránek; J Formánková; M Zichová; J Lachmanová; M Straková; P Broulik; V Pacovský
Journal:  Clin Chim Acta       Date:  1983-09-30       Impact factor: 3.786

6.  Elevation of serum acid phosphatase in cancers with bone metastasis.

Authors:  M Tavassoli; M Rizo; L T Yam
Journal:  Cancer       Date:  1980-05-01       Impact factor: 6.860

7.  Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function.

Authors:  C Minkin
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

8.  Pathogenesis of osteoporosis.

Authors:  B L Riggs
Journal:  Am J Obstet Gynecol       Date:  1987-05       Impact factor: 8.661

  8 in total
  6 in total

1.  Cellular immunodeficiency in Paget's disease of bone: changes induced by treatment with elcatonin.

Authors:  A Rapado; M Yague; M Diaz Curiel; F Ortiz; P Palomino; C de la Piedra; R Torres; B Peramo; E Lopez Gavilanes
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 2.  New developments in biochemical markers for osteoporosis.

Authors:  P Garnero; P D Delmas
Journal:  Calcif Tissue Int       Date:  1996       Impact factor: 4.333

3.  Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism.

Authors:  M Katagiri; T Ohtawa; M Fukunaga; T Harada
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 4.  Biochemical markers of bone turnover for the clinical investigation of osteoporosis.

Authors:  P D Delmas
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

5.  Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget's disease of bone: correlation with other biochemical markers of bone remodelling.

Authors:  R Torres; C de la Piedra; A Rapado
Journal:  Calcif Tissue Int       Date:  1991-07       Impact factor: 4.333

6.  Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.

Authors:  Hartmut H Malluche; Daniel L Davenport; Tom Cantor; Marie-Claude Monier-Faugere
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-19       Impact factor: 8.237

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.